-
公开(公告)号：US20100104651A1
公开(公告)日：2010-04-29
申请号：US12607251
申请日：2009-10-28
申请人： Danchen Gao , Jen-Sen Wu , Wei-Shu Lu , Shouchiung Chen , Pei-Chun Kuo , Chih-Ming Chen
发明人： Danchen Gao , Jen-Sen Wu , Wei-Shu Lu , Shouchiung Chen , Pei-Chun Kuo , Chih-Ming Chen
CPC分类号： A61K31/235 , A61K9/146 , A61K9/1676 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/5078 , A61K47/6951
摘要： A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.
摘要翻译： 公开了一种每日一次的用于治疗炎性或自身免疫疾病或其并发症的双醋瑞因控释制剂，其具有减少的副作用和治疗这些疾病的方法。
-
公开(公告)号：US08536152B2
公开(公告)日：2013-09-17
申请号：US13081548
申请日：2011-04-07
申请人： Mannching Sherry Ku , Danchen Gao , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
发明人： Mannching Sherry Ku , Danchen Gao , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
IPC分类号： A61K31/715
CPC分类号： A61K31/225 , A61K31/145 , A61K31/155 , A61K31/277 , A61K31/426 , A61K31/427 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and/or reducing side effects and/or cardiovascular risks of antidiabetic agents.
摘要翻译： 本发明提供了使用双醋瑞因或其衍生物与其它抗糖尿病药物的组合治疗II型糖尿病的方法。 该方法还可以改善II型糖尿病患者的血糖控制和/或减少抗糖尿病药物的副作用和/或心血管风险。
-
公开(公告)号：US20110251155A1
公开(公告)日：2011-10-13
申请号：US13081548
申请日：2011-04-07
申请人： Mannching Sherry Ku , Danchen Gao , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
发明人： Mannching Sherry Ku , Danchen Gao , Wei-Shu Lu , Chih-Ming Chen , I-Yin Lin
IPC分类号： A61K31/715 , A61P3/10 , A61K31/445 , A61K31/4985 , A61K31/225 , A61K31/4436
CPC分类号： A61K31/225 , A61K31/145 , A61K31/155 , A61K31/277 , A61K31/426 , A61K31/427 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and/or reducing side effects and/or cardiovascular risks of antidiabetic agents.
摘要翻译： 本发明提供了使用双醋瑞因或其衍生物与其它抗糖尿病药物的组合治疗II型糖尿病的方法。 该方法还可以改善II型糖尿病患者的血糖控制和/或减少抗糖尿病药物的副作用和/或心血管风险。
-
4.发明申请公开(公告)号：US20110045522A1
公开(公告)日：2011-02-24
申请号：US12860042
申请日：2010-08-20
申请人： Danchen Gao , Yen-Lun Huang , Feng-Min Lin , Wei-Shu Lu
发明人： Danchen Gao , Yen-Lun Huang , Feng-Min Lin , Wei-Shu Lu
CPC分类号： G01N33/6869 , G01N33/5023 , G01N2333/5412 , G01N2333/5434 , G01N2333/545 , G01N2510/00 , G01N2800/042 , G01N2800/52
摘要： The invention generally relates to novel methods of measuring the effectiveness of a drug for the treatment of diabetes and methods of diagnosing diabetes. In some embodiments of the invention, IL-1Ra is used as a biomarker to measure the effectiveness of a drug for the treatment of diabetes.
摘要翻译： 本发明一般涉及测量用于治疗糖尿病的药物的有效性的新方法和诊断糖尿病的方法。 在本发明的一些实施方案中，IL-1Ra用作生物标志物来测量用于治疗糖尿病的药物的有效性。
-
公开(公告)号：US20060293382A1
公开(公告)日：2006-12-28
申请号：US11453757
申请日：2006-06-14
申请人： Meagan Weldele , David Delmarre , Danchen Gao , Mahmoud El-Khateeb , Carlos-Julian Centeno , Shitalkumar Pathak
发明人： Meagan Weldele , David Delmarre , Danchen Gao , Mahmoud El-Khateeb , Carlos-Julian Centeno , Shitalkumar Pathak
IPC分类号： A61K31/366
CPC分类号： A61K47/10 , A61K9/0019 , A61K9/0095 , A61K31/366 , A61K31/37 , A61K47/02 , A61K47/26
摘要： A stable liquid composition comprising warfarin sodium, glycerin, an alcohol such as ethanol, and a pH buffer such as a phosphate buffer providing a pH above 7 is provided. The stability of the composition is characterized by the amount of warfarin sodium in the composition degraded after 1 month at room temperature, which is 5% or less. A method for preparing the composition and a method for providing an anti-coagulant therapy are also disclosed.
摘要翻译： 提供了包含华法林钠，甘油，醇如乙醇的稳定液体组合物，以及pH缓冲液，例如提供pH高于7的磷酸盐缓冲液。 组合物的稳定性的特征在于组合物中的华法林钠在室温下1个月后降解的量为5％以下。 还公开了制备组合物的方法和提供抗凝血剂治疗的方法。
-
公开(公告)号：US07259185B2
公开(公告)日：2007-08-21
申请号：US11453757
申请日：2006-06-14
申请人： Meagan Erica Weldele , David Delmarre , Danchen Gao , Mahmoud Assad El-Khateeb , Carlos-Julian Sison Centeno , Shitalkumar Ratnakar Pathak
发明人： Meagan Erica Weldele , David Delmarre , Danchen Gao , Mahmoud Assad El-Khateeb , Carlos-Julian Sison Centeno , Shitalkumar Ratnakar Pathak
IPC分类号： A61K31/37 , C07D311/56
CPC分类号： A61K47/10 , A61K9/0019 , A61K9/0095 , A61K31/366 , A61K31/37 , A61K47/02 , A61K47/26
摘要： A stable liquid composition comprising warfarin sodium, glycerin, an alcohol such as ethanol, and a pH buffer such as a phosphate buffer providing a pH above 7 is provided. The stability of the composition is characterized by the amount of warfarin sodium in the composition degraded after 1 month at room temperature, which is 5% or less. A method for preparing the composition and a method for providing an anti-coagulant therapy are also disclosed.
摘要翻译： 提供了包含华法林钠，甘油，醇如乙醇的稳定液体组合物，以及pH缓冲液，例如提供pH高于7的磷酸盐缓冲液。 组合物的稳定性的特征在于组合物中的华法林钠在室温下1个月后降解的量为5％以下。 还公开了制备组合物的方法和提供抗凝血剂治疗的方法。
-
公开(公告)号：US20050267189A1
公开(公告)日：2005-12-01
申请号：US10776869
申请日：2004-02-11
申请人： Danchen Gao , Anthony Hlinak , Ahmad Mazhary , James Truelove , Margaret Vaughn
发明人： Danchen Gao , Anthony Hlinak , Ahmad Mazhary , James Truelove , Margaret Vaughn
IPC分类号： A61K9/14 , A61K20060101 , A61K9/20 , A61K9/48 , A61K31/135 , A61K31/167 , A61K31/415 , A61K31/451 , A61K31/485 , A61K31/55 , A61K31/7056 , A61P20060101 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/10 , A61P11/06 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/04 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/18 , A61P35/00 , A61P37/08 , B02C13/22
CPC分类号： A61K31/635 , A61K9/0053 , A61K9/1694 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2095 , A61K9/4858 , A61K9/4866 , A61K31/415 , A61K45/06
摘要： Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
摘要翻译： 提供药物组合物，其包含一种或多种口服递送剂量单位，每一剂量单位包含与一种或多种药学上可接受的赋形剂紧密混合的约10mg至约1000mg的颗粒塞来昔布。 该组合物可用于治疗或预防环氧合酶-2介导的病症和障碍。
-
公开(公告)号：US20120171284A1
公开(公告)日：2012-07-05
申请号：US13418852
申请日：2012-03-13
IPC分类号： A61K9/48 , A61P29/00 , A61P19/02 , A61P37/00 , A61P11/06 , A61P15/00 , A61P11/00 , A61P17/00 , A61P17/10 , A61P17/16 , A61P17/02 , A61P1/00 , A61P1/04 , A61P27/02 , A61P25/06 , A61P25/00 , A61P9/00 , A61P21/04 , A61P9/10 , A61P3/10 , A61P27/14 , A61P25/28 , A61P37/06 , A61P27/06 , A61P35/00 , A61P7/06 , A61P7/04 , A61P19/04 , A61P43/00 , A61P1/16 , A61P17/06 , A61P13/12 , A61P25/04 , A61K9/28 , A61K31/415
CPC分类号： A61K31/635 , A61K9/0053 , A61K9/1694 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2095 , A61K9/4858 , A61K9/4866 , A61K31/415 , A61K45/06
摘要： Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
摘要翻译： 提供药物组合物，其包含一种或多种口服递送剂量单位，每一剂量单位包含与一种或多种药学上可接受的赋形剂紧密混合的约10mg至约1000mg的颗粒塞来昔布。 该组合物可用于治疗或预防环氧合酶-2介导的病症和障碍。
-
公开(公告)号：US20070166336A1
公开(公告)日：2007-07-19
申请号：US11637677
申请日：2006-12-13
申请人： David Delmarre , Ajit Narang , Kaidi Zhao , Meagan Weldele , Barbara Chen , Carlos-Julian Centeno , Danchen Gao
发明人： David Delmarre , Ajit Narang , Kaidi Zhao , Meagan Weldele , Barbara Chen , Carlos-Julian Centeno , Danchen Gao
IPC分类号： A61K31/405 , A61K9/00
CPC分类号： A61K9/0095 , A61K9/08 , A61K31/4045 , A61K31/405
摘要： The present invention is directed to improved oral liquid compositions that include sumatriptan, or a pharmaceutically acceptable salt or metabolite thereof, and a pharmaceutically acceptable carrier that includes a liquid portion of the composition. The compositions are substantially free of oxidation impurities. Typically, the compositions include a sweetening agent and a flavoring agent, or a bitterness-reducing agent and flavoring agent. Processes of preparing such compositions and methods of administering such compositions are also included.
摘要翻译： 本发明涉及改进的口服液体组合物，其包括舒马曲坦或其药学上可接受的盐或代谢物，以及包括组合物的液体部分的药学上可接受的载体。 组合物基本上不含氧化杂质。 通常，组合物包括甜味剂和调味剂，或减少苦味剂和调味剂。 还包括制备此类组合物的方法和施用此类组合物的方法。
-
公开(公告)号：US20080118570A1
公开(公告)日：2008-05-22
申请号：US11561723
申请日：2006-11-20
申请人： Zhi Liu , Bei Chen , Danchen Gao , Mukti S. Rao , Arunya Usayapant
发明人： Zhi Liu , Bei Chen , Danchen Gao , Mukti S. Rao , Arunya Usayapant
IPC分类号： A61K9/16 , A61K47/48 , A61K31/439 , A61K31/216 , A61K31/4355 , A61K31/137
CPC分类号： A61K31/137 , A61K9/0095 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K31/216 , A61K31/4355 , A61K31/439 , A61K47/585 , A61K47/60 , A61K47/6921
摘要： Included are compositions, and methods of making, coated controlled-release drug and ion exchange resin form complexes. Methacrylate coatings, which can be free of plasticizers particularly with Eudragit® NE type polymer, are preferred to enhance the control of drug release from the drug-resin complexes. Liquid formulations including the coated resin forms and a chelating agent to inhibit degradation are also included.
摘要翻译： 包括组合物和制备方法，包被的控释药物和离子交换树脂形成复合物。 优选不含增塑剂的甲基丙烯酸酯涂料，尤其是用于NE型聚合物，以增强药物 - 树脂复合物的药物释放控制。 还包括包含涂覆的树脂形式的液体制剂和抑制降解的螯合剂。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.031 秒)
